OnabotulinumtoxinA (onaBoNTA) is approved by the US Food and Drug Administration for the treatment of urinary incontinence due to neurogenic detrusor overactivity and for the treatment of refractory overactive bladder.
As a treatment for benign prostatic hyperplasia, onaBoNTA showed no difference over placebo in recently published studies. In contrast, treating interstitial cystitis/bladder pain syndrome (IC/BPS) with onaBoNTA has shown efficacy, and the current American Urological Association guideline for the diagnosis and treatment of IC/BPS lists onaBoNTA as fourth-line treatment. This comprehensive review will present all studied applications of onaBoNTA within the lower urinary tract.
Urology. 2016 Jan 08 [Epub ahead of print]
Christopher J Chermansky, Michael B Chancellor
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, U. S. A. , Department of Urology, Beaumont Health and Oakland University William Beaumont School of Medicine, Royal Oak, MI, U. S. A. .